Aspirin and Colorectal Cancer: The PIK3CA Trial Explained
The ALASCCA trial found low-dose aspirin cut colorectal cancer recurrence in tumors with PI3K pathway changes. Here is what it shows and the bleeding risks.
Supplement and pharmaceutical evidence, held to the same standard, on the same page.
Filtered by ALASCCA · Clear filter
The ALASCCA trial found low-dose aspirin cut colorectal cancer recurrence in tumors with PI3K pathway changes. Here is what it shows and the bleeding risks.